• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022

    10/18/22 10:21:57 AM ET
    $ABT
    $ACMR
    $BAX
    $BBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Machinery/Components
    Technology
    Get the next $ABT alert in real time by email

    Upgrades

    According to Jefferies, the prior rating for Target Corp (NYSE:TGT) was changed from Hold to Buy. Target earned $0.39 in the second quarter, compared to $3.64 in the year-ago quarter. The current stock performance of Target shows a 52-week-high of $254.87 and a 52-week-low of $137.16. Moreover, at the end of the last trading period, the closing price was at $149.25.

    According to Redburn Partners, the prior rating for MongoDB Inc (NASDAQ:MDB) was changed from Sell to Neutral. For the second quarter, MongoDB had an EPS of $0.23, compared to year-ago quarter EPS of $0.24. The stock has a 52-week-high of $519.54 and a 52-week-low of $166.61. At the end of the last trading period, MongoDB closed at $182.35.

    For Diamondrock Hospitality Co (NYSE:DRH), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. In the second quarter, Diamondrock Hospitality showed an EPS of $0.36, compared to $0.05 from the year-ago quarter. At the moment, the stock has a 52-week-high of $11.14 and a 52-week-low of $7.18. Diamondrock Hospitality closed at $8.50 at the end of the last trading period.

    B of A Securities upgraded the previous rating for Owens-Corning Inc (NYSE:OC) from Underperform to Buy. Owens-Corning earned $3.83 in the second quarter, compared to $2.60 in the year-ago quarter. The stock has a 52-week-high of $101.12 and a 52-week-low of $72.97. At the end of the last trading period, Owens-Corning closed at $82.43.

    For Juniper Networks Inc (NYSE:JNPR), Piper Sandler upgraded the previous rating of Underweight to Neutral. In the second quarter, Juniper Networks showed an EPS of $0.42, compared to $0.43 from the year-ago quarter. The current stock performance of Juniper Networks shows a 52-week-high of $38.14 and a 52-week-low of $25.18. Moreover, at the end of the last trading period, the closing price was at $26.61.

    Raymond James upgraded the previous rating for Enviva Inc (NYSE:EVA) from Outperform to Strong Buy. In the second quarter, Enviva showed an EPS of $0.26, compared to $0.24 from the year-ago quarter. At the moment, the stock has a 52-week-high of $91.06 and a 52-week-low of $45.88. Enviva closed at $52.31 at the end of the last trading period.

    According to Goldman Sachs, the prior rating for EOG Resources Inc (NYSE:EOG) was changed from Neutral to Buy. For the second quarter, EOG Resources had an EPS of $2.74, compared to year-ago quarter EPS of $1.73. The stock has a 52-week-high of $147.99 and a 52-week-low of $88.29. At the end of the last trading period, EOG Resources closed at $120.90.

    Cowen & Co. upgraded the previous rating for Xylem Inc (NYSE:XYL) from Market Perform to Outperform. In the second quarter, Xylem showed an EPS of $0.66, compared to $0.66 from the year-ago quarter. At the moment, the stock has a 52-week-high of $121.05 and a 52-week-low of $72.08. Xylem closed at $90.55 at the end of the last trading period.

    According to Barclays, the prior rating for Jamf Holding Corp (NASDAQ:JAMF) was changed from Equal-Weight to Overweight. For the second quarter, Jamf Holding had an EPS of $0.03, compared to year-ago quarter EPS of $0.05. The current stock performance of Jamf Holding shows a 52-week-high of $39.62 and a 52-week-low of $19.20. Moreover, at the end of the last trading period, the closing price was at $21.34.

    RBC Capital upgraded the previous rating for PotlatchDeltic Corp (NASDAQ:PCH) from Sector Perform to Outperform. For the second quarter, PotlatchDeltic had an EPS of $1.61, compared to year-ago quarter EPS of $2.77. The current stock performance of PotlatchDeltic shows a 52-week-high of $60.70 and a 52-week-low of $39.10. Moreover, at the end of the last trading period, the closing price was at $42.63.

    See all analyst ratings upgrades.

    Downgrades

    According to Roth Capital, the prior rating for Acushnet Holdings Corp (NYSE:GOLF) was changed from Buy to Neutral. Acushnet Hldgs earned $0.91 in the second quarter, compared to $1.08 in the year-ago quarter. The current stock performance of Acushnet Hldgs shows a 52-week-high of $53.94 and a 52-week-low of $37.46. Moreover, at the end of the last trading period, the closing price was at $45.76.

    William Blair downgraded the previous rating for Green Dot Corp (NYSE:GDOT) from Outperform to Market Perform. Green Dot earned $0.74 in the second quarter, compared to $0.68 in the year-ago quarter. At the moment, the stock has a 52-week-high of $38.14 and a 52-week-low of $17.50. Green Dot closed at $19.29 at the end of the last trading period.

    Barclays downgraded the previous rating for The Descartes Systems Group Inc (NASDAQ:DSGX) from Equal-Weight to Underweight. In the second quarter, Descartes Systems Gr showed an EPS of $0.27, compared to $0.27 from the year-ago quarter. The current stock performance of Descartes Systems Gr shows a 52-week-high of $82.86 and a 52-week-low of $56.19. Moreover, at the end of the last trading period, the closing price was at $68.36.

    Deutsche Bank downgraded the previous rating for Packaging Corp of America (NYSE:PKG) from Hold to Sell. For the second quarter, Packaging Corp of America had an EPS of $3.23, compared to year-ago quarter EPS of $2.17. At the moment, the stock has a 52-week-high of $168.50 and a 52-week-low of $110.56. Packaging Corp of America closed at $115.94 at the end of the last trading period.

    According to Deutsche Bank, the prior rating for International Paper Co (NYSE:IP) was changed from Hold to Sell. International Paper earned $1.24 in the second quarter, compared to $1.06 in the year-ago quarter. The current stock performance of International Paper shows a 52-week-high of $50.23 and a 52-week-low of $30.69. Moreover, at the end of the last trading period, the closing price was at $33.23.

    For Masco Corp (NYSE:MAS), B of A Securities downgraded the previous rating of Neutral to Underperform. Masco earned $1.14 in the second quarter, compared to $1.14 in the year-ago quarter. The current stock performance of Masco shows a 52-week-high of $71.06 and a 52-week-low of $45.27. Moreover, at the end of the last trading period, the closing price was at $47.81.

    For Hayward Holdings Inc (NYSE:HAYW), B of A Securities downgraded the previous rating of Neutral to Underperform. Hayward Holdings earned $0.29 in the second quarter, compared to $0.31 in the year-ago quarter. At the moment, the stock has a 52-week-high of $26.38 and a 52-week-low of $8.30. Hayward Holdings closed at $9.01 at the end of the last trading period.

    According to Wedbush, the prior rating for Carvana Co (NYSE:CVNA) was changed from Outperform to Neutral. For the second quarter, Carvana had an EPS of $2.35, compared to year-ago quarter EPS of $0.26. The stock has a 52-week-high of $240.58 and a 52-week-low of $17.05. At the end of the last trading period, Carvana closed at $18.22.

    B of A Securities downgraded the previous rating for Mohawk Industries Inc (NYSE:MHK) from Neutral to Underperform. In the second quarter, Mohawk Industries showed an EPS of $4.41, compared to $4.45 from the year-ago quarter. The stock has a 52-week-high of $192.00 and a 52-week-low of $88.84. At the end of the last trading period, Mohawk Industries closed at $96.51.

    According to JMP Securities, the prior rating for Palomar Holdings Inc (NASDAQ:PLMR) was changed from Market Outperform to Market Perform. In the second quarter, Palomar Hldgs showed an EPS of $0.73, compared to $0.51 from the year-ago quarter. The current stock performance of Palomar Hldgs shows a 52-week-high of $95.20 and a 52-week-low of $44.01. Moreover, at the end of the last trading period, the closing price was at $89.16.

    Goldman Sachs downgraded the previous rating for PDC Energy Inc (NASDAQ:PDCE) from Buy to Neutral. In the second quarter, PDC Energy showed an EPS of $5.11, compared to $1.66 from the year-ago quarter. At the moment, the stock has a 52-week-high of $89.22 and a 52-week-low of $48.52. PDC Energy closed at $67.21 at the end of the last trading period.

    For WalkMe Ltd (NASDAQ:WKME), Barclays downgraded the previous rating of Overweight to Equal-Weight. For the second quarter, WalkMe had an EPS of $0.19, compared to year-ago quarter EPS of $0.16. The current stock performance of WalkMe shows a 52-week-high of $19.98 and a 52-week-low of $7.60. Moreover, at the end of the last trading period, the closing price was at $8.05.

    According to Barclays, the prior rating for Pegasystems Inc (NASDAQ:PEGA) was changed from Equal-Weight to Underweight. For the second quarter, Pegasystems had an EPS of $0.38, compared to year-ago quarter EPS of $0.23. The current stock performance of Pegasystems shows a 52-week-high of $111.73 and a 52-week-low of $29.05. Moreover, at the end of the last trading period, the closing price was at $32.34.

    Cowen & Co. downgraded the previous rating for ForgeRock Inc (NYSE:FORG) from Outperform to Market Perform. In the second quarter, ForgeRock showed an EPS of $0.17, compared to $0.40 from the year-ago quarter. The current stock performance of ForgeRock shows a 52-week-high of $27.61 and a 52-week-low of $11.94. Moreover, at the end of the last trading period, the closing price was at $22.54.

    Barclays downgraded the previous rating for UiPath Inc (NYSE:PATH) from Overweight to Equal-Weight. UiPath earned $0.02 in the second quarter, compared to $0.01 in the year-ago quarter. The current stock performance of UiPath shows a 52-week-high of $44.13 and a 52-week-low of $11.10. Moreover, at the end of the last trading period, the closing price was at $12.13.

    Cowen & Co. downgraded the previous rating for KnowBe4 Inc (NASDAQ:KNBE) from Outperform to Market Perform. KnowBe4 earned $0.07 in the second quarter, compared to $0.02 in the year-ago quarter. At the moment, the stock has a 52-week-high of $26.00 and a 52-week-low of $13.78. KnowBe4 closed at $24.49 at the end of the last trading period.

    RBC Capital downgraded the previous rating for NeuBase Therapeutics Inc (NASDAQ:NBSE) from Outperform to Sector Perform. In the third quarter, NeuBase Therapeutics showed an EPS of $0.26, compared to $0.29 from the year-ago quarter. The current stock performance of NeuBase Therapeutics shows a 52-week-high of $3.18 and a 52-week-low of $0.27. Moreover, at the end of the last trading period, the closing price was at $0.31.

    According to UBS, the prior rating for RPM International Inc (NYSE:RPM) was changed from Buy to Neutral. In the first quarter, RPM International showed an EPS of $1.47, compared to $1.08 from the year-ago quarter. At the moment, the stock has a 52-week-high of $101.48 and a 52-week-low of $74.56. RPM International closed at $91.78 at the end of the last trading period.

    According to Goldman Sachs, the prior rating for NGM Biopharmaceuticals Inc (NASDAQ:NGM) was changed from Buy to Neutral. For the second quarter, NGM Biopharmaceuticals had an EPS of $0.59, compared to year-ago quarter EPS of $0.48. At the moment, the stock has a 52-week-high of $19.14 and a 52-week-low of $2.92. NGM Biopharmaceuticals closed at $3.41 at the end of the last trading period.

    For ACM Research Inc (NASDAQ:ACMR), Morgan Stanley downgraded the previous rating of Overweight to Equal-Weight. ACM Research earned $0.22 in the second quarter, compared to $0.06 in the year-ago quarter. The stock has a 52-week-high of $91.59 and a 52-week-low of $7.56. At the end of the last trading period, ACM Research closed at $8.13.

    According to Raymond James, the prior rating for NGM Biopharmaceuticals Inc (NASDAQ:NGM) was changed from Strong Buy to Outperform. For the second quarter, NGM Biopharmaceuticals had an EPS of $0.59, compared to year-ago quarter EPS of $0.48. The stock has a 52-week-high of $19.14 and a 52-week-low of $2.92. At the end of the last trading period, NGM Biopharmaceuticals closed at $3.41.

    RBC Capital downgraded the previous rating for Resolute Forest Products Inc (NYSE:RFP) from Outperform to Sector Perform. In the second quarter, Resolute Forest Prods showed an EPS of $2.00, compared to $3.74 from the year-ago quarter. The current stock performance of Resolute Forest Prods shows a 52-week-high of $21.07 and a 52-week-low of $11.00. Moreover, at the end of the last trading period, the closing price was at $20.86.

    For Syneos Health Inc (NASDAQ:SYNH), JP Morgan downgraded the previous rating of Overweight to Neutral. For the second quarter, Syneos Health had an EPS of $1.25, compared to year-ago quarter EPS of $0.97. At the moment, the stock has a 52-week-high of $102.67 and a 52-week-low of $44.22. Syneos Health closed at $48.19 at the end of the last trading period.

    According to BTIG, the prior rating for RingCentral Inc (NYSE:RNG) was changed from Buy to Neutral. In the second quarter, RingCentral showed an EPS of $0.45, compared to $0.32 from the year-ago quarter. The current stock performance of RingCentral shows a 52-week-high of $194.40 and a 52-week-low of $31.30. Moreover, at the end of the last trading period, the closing price was at $34.29.

    See all analyst ratings downgrades.

    Initiations

    Craig-Hallum initiated coverage on Viant Technology Inc (NASDAQ:DSP) with a Buy rating. The price target for Viant Technology is set to $7.00. Viant Technology earned $0.08 in the second quarter, compared to $0.06 in the year-ago quarter. The stock has a 52-week-high of $10.23 and a 52-week-low of $3.85. At the end of the last trading period, Viant Technology closed at $4.15.

    Lake Street initiated coverage on Domo Inc (NASDAQ:DOMO) with a Buy rating. The price target for Domo is set to $25.00. In the second quarter, Domo showed an EPS of $0.26, compared to $0.30 from the year-ago quarter. At the moment, the stock has a 52-week-high of $57.41 and a 52-week-low of $14.00. Domo closed at $15.78 at the end of the last trading period.

    DA Davidson initiated coverage on PropTech Investment Corp II (NASDAQ:PTIC) with a Buy rating. The price target for PropTech Investment is set to $12.00.

    With an Outperform rating, Keefe, Bruyette & Woods initiated coverage on Esquire Financial Holdings Inc (NASDAQ:ESQ). The price target seems to have been set at $53.00 for Esquire Financial Hldgs. In the second quarter, Esquire Financial Hldgs showed an EPS of $0.78, compared to $0.57 from the year-ago quarter. The current stock performance of Esquire Financial Hldgs shows a 52-week-high of $41.68 and a 52-week-low of $31.59. Moreover, at the end of the last trading period, the closing price was at $38.88.

    Evercore ISI Group initiated coverage on Kimberly-Clark Corp (NYSE:KMB) with an In-Line rating. In the second quarter, Kimberly-Clark showed an EPS of $1.34, compared to $1.47 from the year-ago quarter. The current stock performance of Kimberly-Clark shows a 52-week-high of $145.79 and a 52-week-low of $108.74. Moreover, at the end of the last trading period, the closing price was at $114.18.

    Evercore ISI Group initiated coverage on Clorox Co (NYSE:CLX) with an Underperform rating. For the fourth quarter, Clorox had an EPS of $0.93, compared to year-ago quarter EPS of $0.95. At the moment, the stock has a 52-week-high of $186.86 and a 52-week-low of $120.50. Clorox closed at $133.19 at the end of the last trading period.

    With a Equal-Weight rating, Morgan Stanley initiated coverage on The Trade Desk Inc (NASDAQ:TTD). The price target seems to have been set at $60.00 for Trade Desk. For the second quarter, Trade Desk had an EPS of $0.20, compared to year-ago quarter EPS of $0.18. The stock has a 52-week-high of $93.26 and a 52-week-low of $39.00. At the end of the last trading period, Trade Desk closed at $54.61.

    With a Buy rating, UBS initiated coverage on ProKidney Corp (NASDAQ:PROK). The price target seems to have been set at $18.00 for ProKidney. For the second quarter, ProKidney had an EPS of $0.12, compared to year-ago quarter EPS of $0.09. The current stock performance of ProKidney shows a 52-week-high of $11.98 and a 52-week-low of $6.19. Moreover, at the end of the last trading period, the closing price was at $9.97.

    EF Hutton initiated coverage on Bone Biologics Corp (NASDAQ:BBLG) with a Buy rating. The price target for Bone Biologics is set to $2.25. In the second quarter, Bone Biologics showed an EPS of $0.05, compared to $0.17 from the year-ago quarter. At the moment, the stock has a 52-week-high of $6.78 and a 52-week-low of $0.50. Bone Biologics closed at $0.53 at the end of the last trading period.

    Truist Securities initiated coverage on Keros Therapeutics Inc (NASDAQ:KROS) with a Buy rating. The price target for Keros Therapeutics is set to $100.00. In the second quarter, Keros Therapeutics showed an EPS of $1.13, compared to $0.67 from the year-ago quarter. At the moment, the stock has a 52-week-high of $68.29 and a 52-week-low of $24.38. Keros Therapeutics closed at $46.25 at the end of the last trading period.

    JMP Securities initiated coverage on Benitec Biopharma Inc (NASDAQ:BNTC) with a Market Outperform rating. The price target for Benitec Biopharma is set to $4.00. In the fourth quarter, Benitec Biopharma showed an EPS of $0.62, compared to $0.30 from the year-ago quarter. At the moment, the stock has a 52-week-high of $3.05 and a 52-week-low of $0.20. Benitec Biopharma closed at $0.24 at the end of the last trading period.

    With a Market Outperform rating, JMP Securities initiated coverage on Exelixis Inc (NASDAQ:EXEL). The price target seems to have been set at $26.00 for Exelixis. In the second quarter, Exelixis showed an EPS of $0.28, compared to $0.37 from the year-ago quarter. At the moment, the stock has a 52-week-high of $23.40 and a 52-week-low of $14.87. Exelixis closed at $16.33 at the end of the last trading period.

    Wolfe Research initiated coverage on Simon Property Group Inc (NYSE:SPG) with a Peer Perform rating. Simon Property Group earned $2.91 in the second quarter, compared to $3.24 in the year-ago quarter. The current stock performance of Simon Property Group shows a 52-week-high of $165.83 and a 52-week-low of $86.02. Moreover, at the end of the last trading period, the closing price was at $99.15.

    Barclays initiated coverage on Intuitive Surgical Inc (NASDAQ:ISRG) with an Overweight rating. The price target for Intuitive Surgical is set to $235.00. The current stock performance of Intuitive Surgical shows a 52-week-high of $362.00 and a 52-week-low of $180.07. Moreover, at the end of the last trading period, the closing price was at $190.12.

    Barclays initiated coverage on Abbott Laboratories (NYSE:ABT) with an Overweight rating. The price target for Abbott Laboratories is set to $118.00. For the second quarter, Abbott Laboratories had an EPS of $1.43, compared to year-ago quarter EPS of $1.17. The current stock performance of Abbott Laboratories shows a 52-week-high of $139.83 and a 52-week-low of $96.67. Moreover, at the end of the last trading period, the closing price was at $103.52.

    Barclays initiated coverage on Zimmer Biomet Holdings Inc (NYSE:ZBH) with an Underweight rating. The price target for Zimmer Biomet Holdings is set to $104.00. Zimmer Biomet Holdings earned $1.82 in the second quarter, compared to $1.90 in the year-ago quarter. The stock has a 52-week-high of $135.05 and a 52-week-low of $100.39. At the end of the last trading period, Zimmer Biomet Holdings closed at $110.51.

    Barclays initiated coverage on Baxter International Inc (NYSE:BAX) with an Overweight rating. The price target for Baxter Intl is set to $64.00. In the second quarter, Baxter Intl showed an EPS of $0.87, compared to $0.80 from the year-ago quarter. The stock has a 52-week-high of $89.70 and a 52-week-low of $53.78. At the end of the last trading period, Baxter Intl closed at $55.25.

    With an Overweight rating, Barclays initiated coverage on Tandem Diabetes Care Inc (NASDAQ:TNDM). The price target seems to have been set at $75.00 for Tandem Diabetes Care. In the second quarter, Tandem Diabetes Care showed an EPS of $0.24, compared to $0.06 from the year-ago quarter. The current stock performance of Tandem Diabetes Care shows a 52-week-high of $150.64 and a 52-week-low of $42.90. Moreover, at the end of the last trading period, the closing price was at $55.10.

    Barclays initiated coverage on Boston Scientific Corp (NYSE:BSX) with an Overweight rating. The price target for Boston Scientific is set to $49.00. In the second quarter, Boston Scientific showed an EPS of $0.44, compared to $0.40 from the year-ago quarter. The current stock performance of Boston Scientific shows a 52-week-high of $47.49 and a 52-week-low of $34.98. Moreover, at the end of the last trading period, the closing price was at $40.86.

    Barclays initiated coverage on Stryker Corp (NYSE:SYK) with an Overweight rating. The price target for Stryker is set to $239.00. In the second quarter, Stryker showed an EPS of $2.25, compared to $2.25 from the year-ago quarter. The stock has a 52-week-high of $280.43 and a 52-week-low of $188.84. At the end of the last trading period, Stryker closed at $215.63.

    Barclays initiated coverage on NuVasive Inc (NASDAQ:NUVA) with an Overweight rating. The price target for NuVasive is set to $53.00. For the second quarter, NuVasive had an EPS of $0.47, compared to year-ago quarter EPS of $0.60. The current stock performance of NuVasive shows a 52-week-high of $60.47 and a 52-week-low of $39.57. Moreover, at the end of the last trading period, the closing price was at $42.05.

    With a Equal-Weight rating, Barclays initiated coverage on DexCom Inc (NASDAQ:DXCM). The price target seems to have been set at $103.00 for DexCom. In the second quarter, DexCom showed an EPS of $0.17, compared to $0.19 from the year-ago quarter. At the moment, the stock has a 52-week-high of $539.06 and a 52-week-low of $67.11. DexCom closed at $99.73 at the end of the last trading period.

    Barclays initiated coverage on Medtronic PLC (NYSE:MDT) with a Equal-Weight rating. The price target for Medtronic is set to $90.00. Medtronic earned $1.13 in the first quarter, compared to $1.41 in the year-ago quarter. The current stock performance of Medtronic shows a 52-week-high of $114.31 and a 52-week-low of $79.44. Moreover, at the end of the last trading period, the closing price was at $82.76.

    Barclays initiated coverage on Edwards Lifesciences Corp (NYSE:EW) with an Overweight rating. The price target for Edwards Lifesciences is set to $96.00. For the second quarter, Edwards Lifesciences had an EPS of $0.63, compared to year-ago quarter EPS of $0.64. At the moment, the stock has a 52-week-high of $131.10 and a 52-week-low of $80.69. Edwards Lifesciences closed at $85.49 at the end of the last trading period.

    With an Overweight rating, Barclays initiated coverage on Globus Medical Inc (NYSE:GMED). The price target seems to have been set at $69.00 for Globus Medical. For the second quarter, Globus Medical had an EPS of $0.56, compared to year-ago quarter EPS of $0.56. The stock has a 52-week-high of $81.78 and a 52-week-low of $52.60. At the end of the last trading period, Globus Medical closed at $63.95.

    Barclays initiated coverage on Insulet Corp (NASDAQ:PODD) with a Equal-Weight rating. The price target for Insulet is set to $238.00. For the second quarter, Insulet had an EPS of $0.06, compared to year-ago quarter EPS of $0.23. The stock has a 52-week-high of $283.28 and a 52-week-low of $181.00. At the end of the last trading period, Insulet closed at $224.16.

    With a Buy rating, Rosenblatt initiated coverage on Bentley Systems Inc (NASDAQ:BSY). The price target seems to have been set at $37.00 for Bentley Systems. In the second quarter, Bentley Systems showed an EPS of $0.22, compared to $0.23 from the year-ago quarter. At the moment, the stock has a 52-week-high of $48.91 and a 52-week-low of $26.32. Bentley Systems closed at $32.51 at the end of the last trading period.

    See all analyst ratings initiations.

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $ACMR
    $BAX
    $BBLG

    CompanyDatePrice TargetRatingAnalyst
    Pegasystems Inc.
    $PEGA
    2/12/2026$48.00Equal Weight → Overweight
    Barclays
    Clorox Company
    $CLX
    2/11/2026Underperform → Neutral
    BNP Paribas Exane
    Palomar Holdings Inc.
    $PLMR
    2/9/2026$150.00Outperform
    Evercore ISI
    Medtronic plc.
    $MDT
    2/9/2026$121.00Hold → Buy
    Needham
    Medtronic plc.
    $MDT
    2/3/2026$117.00Buy
    Citigroup
    International Paper Company
    $IP
    2/2/2026$44.00Buy → Neutral
    UBS
    Medtronic plc.
    $MDT
    1/30/2026$114.00Overweight
    Wells Fargo
    Globus Medical Inc.
    $GMED
    1/30/2026$112.00Hold → Buy
    Needham
    More analyst ratings

    $ABT
    $ACMR
    $BAX
    $BBLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Maclin Todd bought $1,041,467 worth of shares (10,000 units at $104.15) (SEC Form 4)

    4 - KIMBERLY CLARK CORP (0000055785) (Issuer)

    2/9/26 4:23:13 PM ET
    $KMB
    Containers/Packaging
    Consumer Discretionary

    Director Maclin Todd transferred by will 134 shares) and bought $38,775 worth of shares (266 units at $145.77), increasing direct ownership by 20% to 2,400 units (SEC Form 4)

    4 - KIMBERLY CLARK CORP (0000055785) (Issuer)

    2/6/26 5:27:22 PM ET
    $KMB
    Containers/Packaging
    Consumer Discretionary

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $ACMR
    $BAX
    $BBLG
    SEC Filings

    View All

    Benitec Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Benitec Biopharma Inc. (0001808898) (Filer)

    2/12/26 8:09:54 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Benitec Biopharma Inc.

    10-Q - Benitec Biopharma Inc. (0001808898) (Filer)

    2/12/26 8:07:48 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Leadership Update, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    2/12/26 7:17:39 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $ABT
    $ACMR
    $BAX
    $BBLG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 28, 2025 - FDA Roundup: February 28, 2025

    For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

    2/28/25 5:00:47 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    March 1, 2024 - FDA Roundup: March 1, 2024

    For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

    3/1/24 4:00:21 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $ABT
    $ACMR
    $BAX
    $BBLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pegasystems upgraded by Barclays with a new price target

    Barclays upgraded Pegasystems from Equal Weight to Overweight and set a new price target of $48.00

    2/12/26 7:19:43 AM ET
    $PEGA
    EDP Services
    Technology

    Clorox upgraded by BNP Paribas Exane

    BNP Paribas Exane upgraded Clorox from Underperform to Neutral

    2/11/26 8:53:35 AM ET
    $CLX
    Specialty Chemicals
    Consumer Discretionary

    Evercore ISI initiated coverage on Palomar Holdings with a new price target

    Evercore ISI initiated coverage of Palomar Holdings with a rating of Outperform and set a new price target of $150.00

    2/9/26 8:16:45 AM ET
    $PLMR
    Property-Casualty Insurers
    Finance

    $ABT
    $ACMR
    $BAX
    $BBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Group Pres., ITT & Pharma. Soriano Maria Cecilia was granted 2,273 shares and covered exercise/tax liability with 918 shares, increasing direct ownership by 2% to 56,006 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    2/11/26 7:11:08 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    EVP and General Counsel Rosenbloom David S. was granted 17,055 shares and covered exercise/tax liability with 5,225 shares, increasing direct ownership by 11% to 119,464 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    2/11/26 7:10:01 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    EVP,Group Pres,Healthcare Rasul Reazur was granted 18,951 shares and covered exercise/tax liability with 5,770 shares, increasing direct ownership by 10% to 139,846 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    2/11/26 7:08:56 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $ABT
    $ACMR
    $BAX
    $BBLG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

    -The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month follow-up timepoint demonstrating durable response to BB-301- -Patient 1 of Cohort 1 completed the 24-month follow-up timepoint, and at the 24-month post-treatment timepoint Patient 1 continued to experience the disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint- - An update on the Interim clinical results for Cohort 2 is planned for mid-2026- -FDA meeting to

    2/12/26 8:30:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acushnet Holdings Corp. to Announce Full Year and Fourth Quarter 2025 Financial Results on February 26, 2026

    News Release to be Available on www.AcushnetHoldingsCorp.com Acushnet Holdings Corp. (NYSE:GOLF) ("Acushnet") will publish its full year and fourth quarter 2025 financial results on February 26, 2026 at approximately 6:30 a.m. Eastern Time. Acushnet will also issue an advisory news release announcing availability of the results via the Acushnet Investor Relations (http://www.acushnetholdingscorp.com/ir) and the U.S. Securities and Exchange Commission (https://www.sec.gov/cgi-bin/browse-edgar?company=acushnet&owner=exclude&action=getcompany) websites on February 26, 2026. Acushnet will hold a conference call for investors at 8:30 a.m. Eastern Time on February 26, 2026 to review the full

    2/12/26 8:00:00 AM ET
    $GOLF
    Recreational Games/Products/Toys
    Consumer Discretionary

    Baxter Reports Fourth-Quarter 2025 Results

    Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis1,2 Fourth-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($2.01); adjusted diluted EPS from continuing operations of $0.44 Company advances ongoing board of directors refreshment Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. "While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise," said And

    2/12/26 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $ABT
    $ACMR
    $BAX
    $BBLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Carvana Co.

    SC 13D/A - CARVANA CO. (0001690820) (Subject)

    12/16/24 6:13:26 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Viant Technology Inc.

    SC 13D/A - Viant Technology Inc. (0001828791) (Subject)

    12/6/24 4:08:19 PM ET
    $DSP
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $ACMR
    $BAX
    $BBLG
    Leadership Updates

    Live Leadership Updates

    View All

    Circana Appoints Highly Regarded Business Leaders to Board of Directors

    Chicago, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Circana LLC, a leading global provider of data, insights, and advisory services, today announced the appointment of three new members to its Board of Directors: Brian Cornell, Executive Chair of Target Corp.; Lauren Cooks Levitan, Co-Founder and Co-CEO of ROOT and Lead Independent Director at e.l.f. Beauty, Inc.; and Rohit Prasad, former Senior Vice President and Head Scientist of Artificial General Intelligence at Amazon.com, Inc. "These appointments strengthen the Board's ability to guide Circana's strategy and accelerate the value we deliver to our global clients," said Stuart Aitken, President and CEO of Circana. "We are focused on advancing

    2/11/26 8:00:00 AM ET
    $AMZN
    $TGT
    Catalog/Specialty Distribution
    Consumer Discretionary
    Department/Specialty Retail Stores

    RingCentral Set to Join S&P SmallCap 600

    NEW YORK, Feb. 9, 2026 /PRNewswire/ -- RingCentral Inc. (NYSE:RNG) will replace Hillenbrand Inc. (NYSE:HI) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, February 12. Lone Star Funds is acquiring Hillenbrand in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Feb 12, 2026 S&P SmallCap 600 Addition RingCentral RNG Information Technology Feb 12, 2026 S&P SmallCap 600 Deletion Hillenbrand HI Industrials ABOUT S&P DOW JONES INDICES S&P Dow Jones Indices is the large

    2/9/26 6:08:00 PM ET
    $HI
    $RNG
    $SPGI
    Miscellaneous manufacturing industries
    Consumer Discretionary
    EDP Services
    Technology

    Pebblebrook Hotel Trust Elects Nina P. Jones and Bill Bayless to Board of Trustees

    The Company also announced the adoption of a New Principles-Based Board Refreshment Framework Pebblebrook Hotel Trust (NYSE:PEB) (the "Company" or "Pebblebrook") today announced the election of Nina P. Jones and Bill Bayless to the Board of Trustees. Ms. Jones's election is effective March 1, 2026. Mr. Bayless is expected to join the Board during the fourth quarter of 2026. Ms. Jones retired from T. Rowe Price, a global investment manager with over $1 trillion in assets under management, where she most recently served as Vice President, Portfolio Manager of the U.S. Real Estate Equity Strategy. She has more than 15 years of real estate investing experience at T. Rowe Price, also serving

    2/9/26 7:00:00 AM ET
    $EQR
    $PEB
    $SPG
    Real Estate Investment Trusts
    Real Estate

    $ABT
    $ACMR
    $BAX
    $BBLG
    Financials

    Live finance-specific insights

    View All

    Acushnet Holdings Corp. to Announce Full Year and Fourth Quarter 2025 Financial Results on February 26, 2026

    News Release to be Available on www.AcushnetHoldingsCorp.com Acushnet Holdings Corp. (NYSE:GOLF) ("Acushnet") will publish its full year and fourth quarter 2025 financial results on February 26, 2026 at approximately 6:30 a.m. Eastern Time. Acushnet will also issue an advisory news release announcing availability of the results via the Acushnet Investor Relations (http://www.acushnetholdingscorp.com/ir) and the U.S. Securities and Exchange Commission (https://www.sec.gov/cgi-bin/browse-edgar?company=acushnet&owner=exclude&action=getcompany) websites on February 26, 2026. Acushnet will hold a conference call for investors at 8:30 a.m. Eastern Time on February 26, 2026 to review the full

    2/12/26 8:00:00 AM ET
    $GOLF
    Recreational Games/Products/Toys
    Consumer Discretionary

    Baxter Reports Fourth-Quarter 2025 Results

    Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis1,2 Fourth-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($2.01); adjusted diluted EPS from continuing operations of $0.44 Company advances ongoing board of directors refreshment Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. "While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise," said And

    2/12/26 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Sylvamo Releases Fourth Quarter, Full Year Earnings

    Sylvamo (NYSE:SLVM), the world's paper company, is releasing fourth quarter and full year 2025 earnings. The company will host an audio webcast at 10 a.m. EST at investors.sylvamo.com. Management Summary from Chief Executive Officer John Sims As Sylvamo's CEO, my vision is that Sylvamo will be legendary for the way we relentlessly pursue and achieve world-class excellence in all that we do. This will create substantial and lasting value for our employees, customers and shareowners and will enable us to be the employer, supplier and investment of choice. I am committed to allocating capital wisely to create long-term value, communicating transparently, upholding our values and driving

    2/12/26 7:00:00 AM ET
    $IP
    $SLVM
    Paper
    Basic Materials